Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

HIV post-exposure prophylaxis

Essential points for quick revision.

Saved on this device
!
A potentially transmissible exposure inside the PEP window

When blood or a relevant sexual fluid has reached susceptible mucosa or broken skin, delay can remove the opportunity to prevent HIV acquisition.

Action: Establish when and how exposure occurred, collect immediately available baseline samples, and give indicated PEP as soon as possible: ideally within 24 hours and never later than 72 hours. Source enquiries and outstanding laboratory results must run alongside treatment rather than postpone the first dose.

Synopsis

Make an exposure-specific PEP decision under time pressure, begin a complete course safely, and connect follow-up testing with longer-term sexual-health prevention.

  • Treat PEP assessment as urgent: an indicated course should start as soon as possible, preferably within 24 hours and no later than 72 hours from exposure.
  • Base the decision on fluid, anatomical route, mucosal or percutaneous injury, source HIV information and documented viral suppression; demographic labels cannot substitute for this history.
  • Draw baseline laboratory HIV, kidney, liver, hepatitis B and C, pregnancy and exposure-site STI samples promptly, while ensuring that testing does not delay the first dose.

Key red flags

A person close to the 72-hour boundary needs a prescribing decision now, with referral arranged after the first dose if PEP is indicated.

Fever, rash, sore throat or lymph-node enlargement that started before this presentation may represent HIV acquired earlier and calls for urgent antigen–antibody and RNA testing.

A reactive or unresolved baseline HIV result changes the task from prevention to diagnostic assessment; a two-drug PrEP regimen must not be used to cover uncertainty.

Renal disease or chronic hepatitis B affects tenofovir and emtricitabine management, but a clearly eligible exposure still needs immediate specialist-supported action.

Pregnancy and breastfeeding require an informed urgent regimen review and are not reasons to refuse otherwise indicated prophylaxis.

After sexual assault, address injuries, emergency contraception, hepatitis B prevention, other STI care, safeguarding and forensic choices in the same trauma-informed pathway.

Eligible sexual route

Condomless receptive anal or vaginal contact can warrant PEP when source virus may be transmissible; timing and reliable suppression determine the decision.

Blood inoculation

A blood-filled hollow-bore needle injury or shared injecting equipment offers direct access through the skin and needs immediate assessment.

Non-intact mucosal contact

Blood reaching an eye, mouth or damaged skin differs clinically from blood resting on intact skin, which does not transmit HIV.

Possible infection predating PEP

A compatible systemic illness already underway may signal earlier acquisition, so RNA testing and specialist review accompany any prevention decision.

Investigation priorities

01
Laboratory fourth-generation HIV assayFirst step

Identify established infection and create the serological starting point for post-course testing.

Management branches

18-hour caseStart without administrative delay

An adult attends 18 hours after receptive anal sex with a source known to have untreated HIV.

  1. Confirm timing, route, fluid, source treatment information, consent circumstances and medicines while checking for injury or other urgent needs.
  2. Collect HIV, renal, liver, hepatitis, pregnancy and site-directed STI samples as applicable without waiting for their results.

Key medicines

Tenofovir disoproxil 245 mg with emtricitabine 200 mgTake one combined tablet by mouth once daily as the backbone of a 28-day PEP course.Review kidney function, concurrent nephrotoxins and hepatitis B; stopping HBV-active therapy in chronic infection requires a planned alternative or liver monitoring.
RaltegravirTake 1200 mg by mouth once daily for 28 days together with tenofovir disoproxil and emtricitabine in the standard UK adult course.Confirm the formulation, check pregnancy and all interactions, and give explicit advice about polyvalent-cation antacids and supplements.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom